Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright

HC Wainwright began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA - Free Report) in a research note published on Thursday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $18.00 price objective on the biopharmaceutical company's stock.

Other research analysts have also issued reports about the stock. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a research note on Thursday, October 24th. They issued a "hold" rating on the stock. Cantor Fitzgerald raised their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an "overweight" rating in a research report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ:VNDA traded up $0.09 during midday trading on Thursday, reaching $4.65. 467,355 shares of the company's stock traded hands, compared to its average volume of 1,323,089. The company has a market cap of $271.05 million, a P/E ratio of -24.84 and a beta of 0.77. The company has a fifty day simple moving average of $4.86 and a two-hundred day simple moving average of $5.23. Vanda Pharmaceuticals has a 1 year low of $3.30 and a 1 year high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. The company had revenue of $50.47 million for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. As a group, research analysts forecast that Vanda Pharmaceuticals will post -0.49 EPS for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of VNDA. SageView Advisory Group LLC acquired a new position in Vanda Pharmaceuticals during the first quarter worth about $34,000. Meeder Asset Management Inc. acquired a new position in Vanda Pharmaceuticals during the second quarter worth about $39,000. ORG Wealth Partners LLC acquired a new position in Vanda Pharmaceuticals during the third quarter worth about $40,000. China Universal Asset Management Co. Ltd. boosted its position in Vanda Pharmaceuticals by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 4,374 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Vanda Pharmaceuticals during the second quarter worth about $61,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.